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Abstract The researches on D-hydantoinase activity and substrate specificity towards
dihydropyrimidine and hydantoin derivatives have been carried out intensively over the last
few decades. So far, the major efforts have focused on (R,S)-5-phenylhydantoin and (R,S)-
5-(4-hydroxyphenyl)hydantoin, the most desirable D-hydantoinase substrates from pharma-
ceutical industry point of view. However, it was shown that D-hydantoinase is a substrate-
dependent enzyme, and its activity and stereoselectivity towards 5-monosubstituted
hydantoins varied significantly with the type of substrate and the source of the enzyme. The
aim of this study was to estimate the substrate specificity of D-hydantoinase towards series of
5-benzylhydantoin derivatives with halogen and methyl substituents in the phenyl ring. The
biotransformations were carried out by using commercial enzyme: immobilized, recombinant,
cloned, and expressed in Escherichia coli D-hydantoinase from Vigna angularis (rD-HYD).
All reactions were monitored by capillary electrophoresis (CE), and the conversion yields were
calculated. Additionally, enantiomeric ratios of the obtained D-phenylalanine derivatives were
estimated by chiral high-performance liquid chromatography (HPLC). Interestingly, the dif-
ferences in the activities of examined enzyme towards particular 5-benzylhydantoin deriva-
tives were observed. CE was also shown as a promising method for monitoring the hydrolysis
of new substrates by D-hydantoinase and further analyzing of enzyme substrate specificity.
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Introduction
Dihidropyrimidinase (EC 3.5.2.2) is a very important enzyme belonging to the cyclic
amidohydrolases superfamily which take part in either pyrimidines or purines catabolism in
bacteria, yeasts, plants, and animals. Dihidropyrimidinase catalyzes the reversible hydrolysis
of 5,6-dihydrouracil as well as the alternative substrates like hydantoin and dihydrothymine [1,
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2]. This enzyme, also known as hydantoinase, is commonly used in hydantoinase method for
obtaining optically pure D- or L-amino acids starting from racemic 5-monosubstituted
hydantoins. In this method, the substrates are hydrolyzed stereoselectively into corresponding
intermediates D- or L-N-carbamoyl-amino acids, which can be further converted to the amino
acids, either chemically with NaNO2/HCl or enzymatically with carbamoylase [3, 4]. The
hydantoinase process has been successfully used for years in pharmaceutical industry for
biosynthesis of D-phenylglycine and D-4-hydroxyphenylglicyne starting from (R,S)-5-
phenylhydantoin and (R,S)-4-hydroxyphenylhydantoin [5]. These two D-amino acids are used
to produce semisynthetic β-lactam antibiotics such as ampicillin or amoxicillin in the reaction
of condensation with 6-aminopenicillanic acid (6-AP). From a pharmaceutical point of view,
D-amino acids are also important as the chiral building blocks of new peptidomimetics. One of
the preferred D-amino acids to design and synthesis of new peptidomimetics is D-phenylala-
nine (D-phe). The hydrophobic activity of D-phe may be responsible for the increased
hydrophobicity of peptidomimetics and may result in better transport properties through
cellular membranes [6]. Additionally, the peptidomimetics containing D-amino acids are
resistant to proteases, peptidases and may by less immunogenic [7, 8]. D-phenylalanine and
its derivatives are the building blocks of many peptidomimetics which have entered the drug
market or are under clinical trials. For instance, D-phe, 4-amino-D-phe, and 4-chloro-D-phe are
the components of following analogs of GnRH hormone: abarelix, acyline, antarelix, azaline b,
antide, cetrorelix, degarelix, ganirelix, iturelix, ornirelix, and Nal-Glu [9, 10]. D-phe was also
used for the synthesis of the analgesic opioid peptide Ac-rfwink-NH2 [11], and nateglinide—
drug stimulating the release of insulin [12]. Another important peptidomimetics containing D-
phe are the analogs of somatostatin hormone, such as synthetic somatostatin analogs:
octreotide and vapreotide [13, 14] or heksarelin, a somatostatin-releasing stimulator [15]. D-
phe was also found in the structure of peptides with strong antibacterial activity isolated from
Bacillus sp.: gramicidin S, tyrocidine A–D [16], bacitracin A [17], and polymyxin B [18]. In
view of increasing importance of D-phe in the design of new peptidomimetics, the
hydantoinase method was successfully applied for the synthesis of the series of halogen and
methyl D-phe derivatives. Taking into account the substrate-dependent properties of D-
hydantoinases, the D-hydantoinase from Vigna angularis—immobilized, recombinant, and
expressed in Escherichia coli—was used to estimate its substrate specificity towards
abovementioned 5-benzylhydantoin derivatives.
Materials and Methods
Chemicals
Unless otherwise stated, hydantoin, benzaldehyde derivatives, red phosphorus, sodium acetate,
ammonium acetate, and solvents which were used in chemical syntheses of 5-benzylhydantoin
derivatives were obtained from commercial suppliers and used without further purification.
Chemical syntheses were carried out as it was described previously [19].
Biotransformations
D-hydantoinase from V. angularis—immobilized, recombinant, cloned, and expressed in
E. coli (53.1 U/g using hydantoin as a substrate)—was obtained from Sigma-Aldrich. The
(R,S)-5-benzylhydantoin derivatives were first dissolved in 100 μl of dimethyl sulfoxide
(DMSO) and, next, the borate buffer pH 8.9 (MERCK) up to the concentration of 1 mM
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was added. All biotransformations were carried out with 10 mg of examined D-hydantoinase
suspended in a 2-ml solution of 1 mM 5-benzylhydantoin derivative in borate buffer pH 8.9 on
the orbital shaker 120 rpm at 37 °C for 48 or 72 h (Fig. 1). The D-hydantoinase was next
removed using 0.2-μm membrane filter (Whatman) and the obtained N-carbamoyl-D-phe
derivatives were converted into the corresponding D-phe derivatives using a diazotization
reaction. For this purpose, the reaction mixture was acidified first with 3.5 M HCl to pH 1.0
and next 5 μl of 3.5 M NaNO2 was added. Then, the reaction mixture was stored on ice for 6 h.
The reaction was stopped by alkalization to pH 9.0 with 3.5 M NaOH (Fig. 2).
Analysis
To calculate the calibration curves, the following concentrations of each substrate were used: 1,
0.7, 0.5, 0.1, and 0.02 mM. The calibration curves were estimated by Beckman capillary
electrophoresis (CE) system (P/ACE MDQ) controlled by 32 Karat Software version 8.0 and
equipped with diode-array detector (DAD). An uncoated fused-silica capillary with total length
of 60 cm (50.2 cm to detection window) and internal diameter 75 μm was also purchased from
Beckman. DMSO was used as an internal standard and electroosmotic flow (EOF) marker for
all separations. All analyses by CE were performed at room temperature, applying a voltage of
20 kV and at pH 8.9 of the background electrolyte. The time-course curves of reaction were
followed by CE determination of concentration of the respective (R,S)-5-benzylhydantoin
derivative. Data were collected after 6, 24, and 48 h and additionally, if total conversion was
not observed, after 72 h of the reaction. The experiments were performed once. To demonstrate
the reproducibility, the reactions for the one substrate (R1) were conducted in three repetitions.
Data were collected after 1, 3, 6, 24, 48, and 72 h and the standard deviations from three
independent experiments were calculated (Fig 3). Enantiomeric excess (ee) of the obtained
Fig. 1 The production of N-carbamoyl-D-phe derivatives using rD-HYD
Fig. 2 The production of D-phe derivatives from N-carbamoyl-D-phe using the reaction of diazotization
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D-phe derivatives was measured using HPLC Dionex P580 instrument equipped with a
ChiroSil (RCA+) column containing the chiral stationary phase prepared by a covalent
trifunctional bonding of (+) or (−)-(18-crown-6)-tetracarboxylic acid. The mobile phase was
prepared according to the manufacturer’s instructions dedicated for the enantioseparation of
D,L-phenylalanine and was composed of 70 % methanol/30 % 10 mM CH3COOH. The flow
rate was 1.5 ml/min, the temperature 25 °C, and the detection wavelength 225 nm.
Results and Discussion
There are many examples in the literature describing the ability of D-hydantoinase to hydrolyze
the broad range of substrates. However, the activity of this enzyme as well as enantioselectivity
was proven to be substrate-dependent. For instance, the D-hydantoinase obtained from adzuki
bean (V. angularis) was shown to be 5.3–7 fold more active against (R,S)-phenylhydantoin,
than against (R,S)-4-hydroxyphenylhydantoin [20]. Another important example was the
enantioseletivity of D-hydantoinase from Arthrobacter aurescens DSM 3745, which differed
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Fig. 3 The bioconversion of (R,S)-5-benzylhydantoin (R1) with calculated standard deviations from three
independent experiments
Table 1 Biotransformations effi-
ciency and enantioselectivity
R substrate, ee enantiomeric
excess
aConversion after 48 h
R ee (%) Conversion (%)
R1 95.51 89.97
R2 78.86 87.32
R3 92.76 92.13
R4 79.18 89.95
R5 97.82 88.06
R6 77.30 99.53a
R7 87.58 99.68a
R8 95.73 97.36a
R9 92.53 100a
R10 93.38 100a
R11 94.33 100a
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according to the used substrate. The biotransformation catalyzed by this enzyme was L-
selective for indolylmethylhydantoin, non-selective for methylthioethylhydantoin (with slight
preference for the D-enantiomer), and D-selective for methylhydantoin [21]. Several bacterial
strains with D-hydantoinase activity and additionally three recombinant D-hydantoinases were
shown to be able to produce N-carbamoyl-β-phenylalanine from racemic 6-phenyl-5,6-
dihydrouracil. However, the enantiomeric excess of the obtained D-enantiomer depended on
biocatalyst and was from 6 to 96 %, while one reaction resulted surprisingly in 61 % of
enaniomeric excess of L-enantiomer. Additionally, the conversion efficiency of these reactions
varied from 12 to 85 % [22]. Moreover, our recent studies on (R,S)-5-benzylhydantoin
derivatives biotransformation by D-hydantoinase showed differences in bioconversion effi-
ciency and enantioselectivity with the preference to the substrates possessing the substituent in
the 4-position of phenyl ring [23]. The docking studies and the study on modification of the
enzyme’ s hydrophobic-binding pocket by mutagenesis showed also the correlation between
the size of the substrate, its spatial orientation, and accessing to the catalytic center of D-
hydantoinase [24, 25]. During this study, we used capillary electrophoresis as a tool for
monitoring the progress of the substrate hydrolysis and to calculate the reaction efficiency
catalyzed by rD-HYD. Additionally, the chiral high-performance liquid chromatography
0 20 40 60 80
0.0
0.2
0.4
0.6
0.8
1.0
R3
R2
R4
R5
t [h]
c 
[m
M
]
Fig. 4 The bioconversion of (R,S)-5-benzylhydantoin derivatives R2–R5 with rD-HYD in sodium borate buffer
pH 8.9 at 37 °C for 72 h
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Fig. 5 The bioconversion of (R,S)-5-benzylhydantoin derivatives R6–R11 with rD-HYD in sodium borate buffer
pH 8.9 at 37 °C for 48 h
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(HPLC) technique was applied to determine the enantiomeric ratios of obtained D-phenylal-
anine derivatives. As it was presented in Table 1, all substrates were successfully converted
into N-carbamoyl-D-amino acids with very high bioconversion efficiency from 87.32 to
100 %. However, we observed the greater preference of the examined enzyme rather to the
substrates with halogen (R6–R11) than with methyl (R2–R5) substituents. All fluorine- and
bromine-substituted substrates were converted with almost 100 % efficiency after 48 h of
incubation, whereas none of methyl-substituted substrates was completely hydrolyzed after
72 h (Figs. 4 and 5). Moreover, all the bromine-substituted (R9–R11) derivatives were
converted with more than 80 % efficiency as early as 6 h of incubation (Fig. 5). The
comparison of enantiomeric ratios of the obtained D-phenylalanine derivatives showed that
the high conversion efficiency of halogen derivatives by rD-HYD was not always affected on
its enantioselectivity. For instance, despite of the almost 100 % bioconversion efficiency of 2-
fluorine benzylhydantoin derivative R6, the enantiomeric excess of obtained 2-fluorine-D-
phenylalanine was the lowest among all examined products and resulted only 77.30 %.
However, all bromine D-phenylalanine derivatives (R9–R11) were obtained with high
enantiomeric purity from 92.53 to 94.33 % as well as with the highest conversion efficiency
among all examined reactions, indicating distinctly the substrate preferences of rD-HYD
(Table 1). Interestingly, the noticed previous preference of that enzyme to (R,S)-5-
benzylhydantoin derivatives with substituent in 4-position [23] in case of methyl and halogen
derivatives was not observed. Thus, further docking analyses and the study on the potential
influence of (R,S)-5-benzylhydantoin derivatives racemization or product inhibition on rD-
HYD stereoselectivity and reaction efficiency should be performed.
Acknowledgments The authors acknowledge the financial support of the Polish Ministry of Health and Higher
Education grant N405 2518 33.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which
permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are
credited.
References
1. Syldatk, C., May, O., Altenbuchner, J., Mattes, R., & Siemann, M. (1999). Applied Microbiology and
Biotechnology, 51, 293–309.
2. Barba, M., Glansdorff, N., & Labedan, B. (2013). Journal of Molecular Evolution, 77, 70–80.
3. Takahashi, S., Ohashi, T., Kii, Y., & Kumagai, H. (1979). Journal of Fermentation Technology, 4, 328–332.
4. Altenbuchner, J., Siemann-Herzberg,M., & Syldatk, C. (2001).Current Opinion in Biotechnology, 12, 559–563.
5. Takahashi, S. (1986). Progress in Industrial Microbiology, 24, 269–279.
6. Wang, W., Xiong, C., Zhang, J., & Hruby, V. J. (2002). Tetrahedron, 58, 7365–7374.
7. Pappenheimer, J. R., Dahl, C. E., Karnovsky, M. L., & Maggio, J. E. (1994). Proceedings of the National
Academy of Sciences, 91, 1942–1945.
8. Chong, P., Sia, C., Tripet, B., James, O., & Klein, M. (1996). Letters in Peptide Science, 3, 99–106.
9. Herbst, K. (2003). Current Opinion in Pharmacology, 3, 660–666.
10. Martinez-Rodriguez, S., Martinez-Gomez, A. I., Rodriguez-Vico, F., Clemente-Jimenez, J. M., & Las Heras-
Vazquez, F. J. (2010). Chemistry & Biodiversity, 7, 1531–1548.
11. Dooley, C. T., Chung, N. N., Wilkes, B. C., Schiller, P. W., Bidlack, J. M., Pasternak, G. W., & Houghten, R.
A. (1994). Science, 266, 2019–2022.
12. Tentolouris, N., Voulgari, C., &Katsilambros, N. (2007). Vascular Health and Risk Management, 3, 797–807.
13. Dasgupta, P. (2004). Pharmacology & Therapeutics, 102, 61–85.
14. Susini, C., & Buscail, L. (2006). Annals of Oncology, 17, 1733–1742.
15. Melis, M. R., Succu, S., Spano, M. S., Torsello, A., Locatelli, V., Muller, E. E., Deghenghi, R., & Argiolas,
A. (2000). European Journal of Pharmacology, 404, 137–143.
Appl Biochem Biotechnol (2015) 175:698–704 703
16. Katz, E., & Demain, A. L. (1977). Bacteriological Reviews, 41, 449–474.
17. Ikai, Y., Oka, H., Hayakawa, J., Matsumoto, M., Saito, M., Harada, K., Mayumi, Y., & Suzuki, M. (1995).
Journal of Antibiotics, 48, 233–242.
18. Banerjee, A. B., & Bose, S. K. (1963). Nature, 200, 471.
19. Latacz, G., Pękala, E., Ciopińska, A., & Kieć-Kononowicz, K. (2006). Acta Poloniae Pharmaceutica, 63,
430–433.
20. Fan, C. H., & Lee, C. K. (2001). Biochemical Engineering Journal, 8, 157–164.
21. May, O., Siemann, M., Pietzsch, M., Kiess, M., Mattes, R., & Syldatk, C. (1998). Journal of Biotechnology,
61, 1–13.
22. Engel, U., Syldatk, C., & Rudat, J. (2012). Applied Microbiology and Biotechnology, 94, 1221–1231.
23. Latacz, G., & Kieć-Kononowicz, K. (2014). Biocatalysis and Biotransformation, 32, 117–124.
24. Lee, S. C., Chang, Y. J., Shin, D. M., Han, J., Seo, M. H., Fazelinia, H., Maranas, C. D., & Kim, H. S.
(2009). Enzyme and Microbial Technology, 44, 170–175.
25. Cai, Y., Trodler, P., Jiang, S., Zhang, W., Wu, Y., Lu, Y., Yang, S., & Jiang, W. (2009). The FEBS Journal,
276, 3575–3588.
704 Appl Biochem Biotechnol (2015) 175:698–704
